{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:16:14Z","timestamp":1777936574826,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:p>With continued progress and success in clinical care, the management of patients with Hodgkin lymphoma (HL) has undergone continuous revision to improve patient care outcomes and limit acute and late treatment effects on normal tissue imposed by therapy. Hodgkin lymphoma is a disease that affects children, adolescents, and adults. Clinical management strategies are influenced by the patient\u2019s age at diagnosis, tumor burden, response to induction therapy, and potential expectation of treatment impact on normal tissue. The approach to patient management varies in many parts of the world and is influenced by treatment availability, physician training, and medical culture. Differences in approach are important to understand for accurately comparing and contrasting outcome studies. In this article, we will identify current areas of common ground and points of separation in patient care management for HL. Opportunities for clinical trial strategies will be defined for future clinical trials.<\/jats:p>","DOI":"10.1177\/1179554918754885","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T03:26:49Z","timestamp":1517369209000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States\/North America: Evolving Trends in Protocol Therapy"],"prefix":"10.1177","volume":"12","author":[{"given":"Thomas J","family":"FitzGerald","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA, USA"},{"name":"Department of Radiation Oncology, UMass Memorial Health Care, Worcester, MA, USA"},{"name":"Quality Assurance Review Center, Department of Radiation Oncology, University of Massachusetts Medical School, Lincoln, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryann","family":"Bishop-Jodoin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA, USA"},{"name":"Quality Assurance Review Center, Department of Radiation Oncology, University of Massachusetts Medical School, Lincoln, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"bibr1-1179554918754885","unstructured":"Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: Hodgkin lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessed March 20, 2017."},{"key":"bibr2-1179554918754885","unstructured":"ClinicalTrials.gov Background. https:\/\/clinicaltrials.gov\/ct2\/about-site\/background. Accessed November 6, 2017."},{"key":"bibr3-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp030049"},{"key":"bibr4-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0906731"},{"key":"bibr5-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2769"},{"key":"bibr6-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.2387"},{"key":"bibr7-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20546"},{"key":"bibr8-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184143"},{"key":"bibr9-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1819"},{"key":"bibr10-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.007"},{"key":"bibr11-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.514"},{"key":"bibr12-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.5410"},{"key":"bibr13-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.11.034"},{"key":"bibr14-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.10.028"},{"key":"bibr15-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181f4686e"},{"key":"bibr16-1179554918754885","doi-asserted-by":"publisher","DOI":"10.17226\/18362"},{"key":"bibr17-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.10.008"},{"key":"bibr18-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.578.578"},{"key":"bibr19-1179554918754885","unstructured":"Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma. US National Library of Medicine, 2017. https:\/\/clinicaltrials.gov\/beta\/show\/NCT01118026. Accessed January 12, 2017."},{"key":"bibr20-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"bibr21-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"bibr22-1179554918754885","unstructured":"Brentuximab vedotin and combination chemotherapy in treating children and young adults with stage IIB or stage IIIB-IVB Hodgkin lymphoma. US National Library of Medicine, 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02166463. Accessed December 12, 2017."},{"key":"bibr23-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.764.764"},{"key":"bibr24-1179554918754885","doi-asserted-by":"crossref","unstructured":"Pieters RS. The impact of protocol assignment for older adolescents with Hodgkin lymphoma. 2014;4:317.","DOI":"10.3389\/fonc.2014.00317"},{"key":"bibr25-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7"},{"key":"bibr26-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.0482"},{"key":"bibr27-1179554918754885","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert A","year":"2003","journal-title":"J Clin Oncol"},{"key":"bibr28-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"bibr29-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018"},{"key":"bibr30-1179554918754885","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann P","year":"2011","journal-title":"J Clin Oncol"},{"key":"bibr31-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"bibr32-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"bibr33-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi023"},{"key":"bibr34-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2252"},{"key":"bibr35-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"bibr36-1179554918754885","unstructured":"Chemotherapy followed by radiation therapy in treating young patients with newly diagnosed Hodgkin\u2019s disease. US National Library of Medicine, 2004. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00002827?id=9426&rank=1. Accessed December 13, 2017."},{"key":"bibr37-1179554918754885","unstructured":"Combination chemotherapy with or without dexrazoxane in treating children with Hodgkin\u2019s disease. US National Library of Medicine, 2004. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00005578?id=9425&rank=1. Accessed December 13, 2017."},{"key":"bibr38-1179554918754885","unstructured":"Chemotherapy with or without additional chemotherapy and\/or radiation therapy in treating children with newly diagnosed Hodgkin\u2019s disease. US National Library of Medicine, 2003. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00025259?id=ahod0031&rank=1. Accessed December 13, 2017."},{"key":"bibr39-1179554918754885","unstructured":"Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma. US National Library of Medicine, 2010. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01132807?id=50604&rank=1. Accessed December 13, 2017."},{"key":"bibr40-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.578.578"},{"key":"bibr41-1179554918754885","unstructured":"Combination chemotherapy with or without radiation therapy in treating patients with Hodgkin\u2019s lymphoma. US National Library of Medicine, 2003. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00003389?id=2496&rank=5. Accessed December 1, 2017."},{"key":"bibr42-1179554918754885","unstructured":"S0816 fludeoxyglucose F 18-PET\/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma. US National Library of Medicine, 2009. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00822120?id=s0816&rank=1. Accessed December 11, 2017."},{"key":"bibr43-1179554918754885","unstructured":"HD11 for intermediate stages. US National Library of Medicine, 2005. https:\/\/clinicaltrials.gov\/show\/NCT00264953. Accessed December 11, 2017."},{"key":"bibr44-1179554918754885","unstructured":"HD12 for advanced stages. US National Library of Medicine, 2005. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00265031?id=HD12&rank=2. Accessed December 11, 2017."},{"key":"bibr45-1179554918754885","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554918754885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1179554918754885","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554918754885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:52Z","timestamp":1777693012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1179554918754885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":45,"alternative-id":["10.1177\/1179554918754885"],"URL":"https:\/\/doi.org\/10.1177\/1179554918754885","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"1179554918754885"}}